Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives

European Heart Journal

Volumn 34, Issue 11, 2013, Pages

  Jankowska, Ewa A ^a,b   Von Haehling, Stephan ^c   Anker, Stefan D ^c,d   MacDougall, Iain C ^e   Ponikowski, Piotr ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Exercise capacity; Heart failure; Hepcidin; Iron deficiency; Prognosis; Soluble transferrin receptor

Indexed keywords

HEPCIDIN; IRON; TRANSFERRIN RECEPTOR;

COMORBIDITY; DEPRESSION; DIETARY INTAKE; DISEASE CLASSIFICATION; EXERCISE; EXERCISE TOLERANCE; HEART FAILURE; HEART PROTECTION; HOMEOSTASIS; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE;

CARDIOMYOPATHIES; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; DIETARY SUPPLEMENTS; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; IRON; IRON, DIETARY; MUSCULAR DISEASES; PROGNOSIS;

EID: 84875205478     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs224     Document Type: Review

References (146)

1. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;8:2.
2. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370: 511-520.
3. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
4. Milman N. Anemia-still a major health problem in many parts of the world! Ann Hematol 2011;90:369-377.
5. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, Mathers C, Rivera J; Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008;371:243-260.
6. Haas JD, Brownlie T IV. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131: 676S-690S.
7. Baker JF, Ghio AJ. Iron homoeostasis in rheumatic disease. Rheumatology 2009; 48:1339-1344.
8. Balla J, Jeney V, Varga Z, Komo di E, Nagy E, Balla G. Iron homeostasis in chronic inflammation. Acta Physiol Hung 2007;94:95-106.
9. Zafon C, Lecube A, Simo R. Iron in obesity. An ancient micronutrient for a modern disease. Obes Rev 2010;11:322-328.
10. Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009;15:4659-4665.
11. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-693.
12. Somers K. Acute reversible heart failure in severe iron-deficiency anemia associated with hookworm infestation in Uganda Africans. Circulation 1959;19: 672-675.
13. Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation 1969;39:503-515.
14. Turner LR, Premo DA, Gibbs BJ, Hearthway ML, Motsko M, Sappington A, Walker L, Mullendore ME, Chew HG Jr. Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. BMC Physiol 2002;2:1.
15. Tanne Z, Coleman R, Nahir M, Shomrat D, Finberg JP, Youdim MB. Ultrastructural and cytochemical changes in the heart of iron-deficient rats. Biochem Pharmacol 1994;47:1759-1766.
16. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009;296:H585-H593.
17. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci 2005;109:277-286.
18. Silverberg DS,Wexler D, Iaina A, Schwartz D. The role of correction of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 2008;10: 819-823.
19. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results fromVal-Heft. Circulation 2005;112: 1121-1127.
20. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1441-1446.
21. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR, Piepoli MF, Anker SD, Banasiak W, Ponikowski P. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 2003;90:303-308.
22. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, Poole-Wilson PA, Coats AJ, Anker SD. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888-891.
23. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223-225.
24. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485-2489.
25. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-2237.
26. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009;16:94-100.
27. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008;4:47-57.
28. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008;15: 169-175.
29. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-535.
30. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia. Eur Heart J 2007;28: 2208-2216.
31. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol 2007;49:753-762.
32. Hower V, Mendes P, Torti FM, Laubenbacher R, Akman S, Shulaev V, Torti SV. A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst 2009;5:422-443.
33. Fairbanks V, Beutler E. Iron deficiency. In: Beutler E (ed.), Williams Hematology. 6th ed. New York: McGraw-Hill; 2001, p295-304 and p447-50.
34. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007;17:93-100.
35. Cairo G, Bernuzzi F, Recalcati S. A precious metal: iron, an essential nutrient for all cells. Genes Nutr 2006;1:25-39.
36. Carrondo MA. Ferritins, iron uptake and storage from the bacterioferritin viewpoint. EMBO J 2003;22:1959-1968.
37. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(Suppl 2):568S-579S.
38. Rouault TA, Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 2005;6:345-351.
39. Huang ML, Lane DJ, Richardson DR. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal 2011;15:3003-3019.
40. Galy B, Ferring-Appel D, Sauer SW, Kaden S, Lyoumi S, Puy H, Kolker S, Grone HJ, Hentze MW. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab 2010;12:194-201.
41. Camaschella C, Pagani A. Iron and erythropoiesis: a dual relationship. Int J Hematol 2011;93:21-26.
42. Alcantara O, Boldt DH. Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1). Br J Haematol 2007;137: 252-261.
43. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009;81:412-419.
44. Ventura-Clapier R. Exercise training, energy metabolism, and heart failure. Appl Physiol Nutr Metab 2009;34:336-339.
45. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-1837.
46. Rosca MG, Hoppel CL. Mitochondria in heart failure. Cardiovasc Res 2010;88: 40-50.
47. Turer AT, Malloy CR, Newgard CB, Podgoreanu MV. Energetics and metabolism in the failing heart: important but poorly understood. Curr Opin Clin Nutr Metab Care 2010;13:458-465.
48. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010;84:825-889.
49. Xu J, Marzetti E, Seo AY, Kim JS, Prolla TA, Leeuwenburgh C. The emerging role of iron dyshomeostasis in the mitochondrial decay of aging. Mech Ageing Dev 2010;131:487-493.
50. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211.
51. Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, Paturi S, Arvapalli RK, Katta A, Kakarla SK, Rice KM, Triest WE, Blough ER. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 2011;336: 56-63.
52. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program 2003;1:40-61.
53. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139:393-408.
54. Munoz JP, Chiong M, Garc?a L, Troncoso R, Toro B, Pedrozo Z, Diaz-Elizondo J, Salas D, Parra V, Nunez MT, Hidalgo C, Lavandero S. Iron induces protection and necrosis in cultured cardiomyocytes: role of reactive oxygen species and nitric oxide. Free Radic Biol Med 2010;48:526-534.
55. Munoz M, Garc?a-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011;64:281-286.
56. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009;1:207-214.
57. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
58. Anderson GJ, Frazer DM, McLaren GD. Iron absorption and metabolism. Curr Opin Gastroenterol 2009;25:129-135.
59. Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci 2009;66: 3241-3261.
60. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434:365-381.
61. Koorts AM, Viljoen M. Ferritin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion. Arch Physiol Biochem 2007;113: 30-54.
62. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-741.
63. Viatte L, Vaulont S. Hepcidin, the iron watcher. Biochimie 2009;91:1223-1228.
64. Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010;411:1565-1569.
65. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122:78-86.
66. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;13:393-404.
67. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-97.
68. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, Bilo G, Revera M, Giuliano A, Faini A, Mainini V, Westerman M, Ganz T, Valsecchi MG, Mancia G, Parati G; HIGHCARE investigators. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011;117:2953-2959.
69. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1(Suppl 1):S4-S8.
70. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-4761.
71. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010;26:473-482.
72. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, Roger SD, Savoia HF, Tampi R, Thomson AR, Wood EM, Robinson KL. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 2010;193:525-532.
73. Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 2009;18:345-352.
74. Moreno Chulilla JA, Romero Colas MS, Gutierrez Mart?n M. Classification of anemia for gastroenterologists. World J Gastroenterol 2009;15:4627-4637.
75. Goddard AF, James MW, McIntyre AS, Scott BB; on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 2011;60:1309-1316.
76. Gale E, Torrance J, Bothwell T. The quantitative estimation of total iron stores in human bone marrow. J Clin Invest 1963;42:1076-1082.
77. Phiri KS, Calis JC, Kachala D, Borgstein E, Waluza J, Bates I, Brabin B, van Hensbroek MB. Improved method for assessing iron stores in the bone marrow. J Clin Pathol 2009;62:685-689.
78. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol 2009;31:277-297.
79. Ali MA, Luxton AW, Walker WH. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J 1978;118:945-946.
80. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observerblinded trial. J Am Coll Cardiol 2008;51:103-112.
81. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, for the FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
82. Piva E, Brugnara C, Chiandetti L, Plebani M. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. Clin Chem Lab Med 2010;48:1369-1380.
83. Buttarello M, Plebani M. Automated blood cell counts: state of the art. Am J Clin Pathol 2008;130:104-116.
84. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci 2010;55:548-559.
85. Allen LA, Felker GM, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, Lenihan DJ, Oren RM, Wagoner LE, Schwartz TA, Adams KF Jr. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail 2010;16:230-238.
86. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007;50:40-47.
87. van Kimmenade RR, Mohammed AA, Uthamalingam S, van der Meer P, Felker GM, Januzzi JL Jr. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail 2010;12:129-136.
88. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation 2010;121:245-251.
89. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008;29: 1510-1515.
90. Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83:872-875.
91. Chang J, Bird R, Clague A, Carter AC. Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients. Pathology 2007;39:349-353.
92. Chua E, Clague JE, Sharma AK, Horan MA, Lombard M. Serum transferrin receptor assay in iron deficiency anaemia and anaemia of chronic disease in the elderly. QJM 1999;92:587-594.
93. Rimon E, Levy S, Sapir A, Gelzer G, Peled R, Ergas D, Sthoeger ZM. Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. Arch Intern Med 2002;162:445-449.
94. Hughes CM, Woodside JV, McGartland C, Roberts MJ, Nicholls DP, McKeown PP. Nutritional intake and oxidative stress in chronic heart failure. Nutr Metab Cardiovasc Dis 2012;22:376-382.
95. Lourenco BH, Vieira LP, Macedo A, Nakasato M, Marucci Mde F, Bocchi EA. Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. Arq Bras Cardiol 2009;93:541-548.
96. Naito Y, Tsujino T, Fujimori Y, Sawada H, Akahori H, Hirotani S, Ohyanagi M, Masuyama T. Impaired expression of duodenal iron transporters in Dahl saltsensitive heart failure rats. J Hypertens 2011;29:741-748.
97. Srai SK, Chung B, Marks J, Pourvali K, Solanky N, Rapisarda C, Chaston TB, Hanif R, Unwin RJ, Debnam ES, Sharp PA. Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int 2010;78: 660-667.
98. Simpson RJ, McKie AT. Regulation of intestinal iron absorption: the mucosa takes control? Cell Metab 2009;10:84-87.
99. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 2006;70:434-445.
100. Satoh M, Minami Y, Takahashi Y, Nakamura M. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep 2008;5:69-74.
101. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008;14:61-74.
102. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1-5.
103. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010; 1:129-133.
104. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28.
105. Simonis G, Mueller K, Schwarz P, Wiedemann S, Adler G, Strasser RH, Kulaksiz H. The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction. Peptides 2010;31: 1786-1790.
106. Suzuki H, Toba K, Kato K, Ozawa T, Tomosugi N, Higuchi M, Kusuyama T, Iso Y, Kobayashi N, Yokoyama S, Fukuda N, Saitoh H, Akazawa K, Aizawa Y. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku J Exp Med 2009;218:93-98.
107. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Akahori H, Sakoda T, Ohyanagi M, Tomosugi N, Masuyama T. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J 2010;74:301-306.
108. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/ chronic heart failure patients. Eur J Heart Fail 2010;12:943-950.
109. Divakaran V, Mehta S, Yao D, Hassan S, Simpson S, Wiegerinck E, Swinkels DW, Mann DL, Afshar-Kharghan V. Hepcidin in anemia of chronic heart failure. Am J Hematol 2011;86:107-109.
110. Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mortl D, Kletter K, Maurer G, Lang IM, Pacher R. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008; 29:2343-2350.
111. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004;147:924-930.
112. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1880.
113. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011;17:899-906.
114. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-1665.
115. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225-1227.
116. Varma A, Appleton DL, Nusca A, Lipinski MJ, Goudreau E, Cowley MJ, Wittkamp M, Vetrovec GW, Abbate A. Iron deficiency anemia and cardiac mortality in patients with left ventricular systolic dysfunction undergoing coronary stenting. Minerva Cardioangiol 2010;58:1-10.
117. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010;3:537-546.
118. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996;28:1092-1102.
119. Toblli JE, Cao G, Rivas C, Kulaksiz H. Heart and iron deficiency anaemia in rats with renal insufficiency: the role of hepcidin. Nephrology 2008;13:636-645.
120. Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007;148:2663-2668.
121. Ge XH,Wang Q, Qian ZM, Zhu L, Du F, Yung WH, Yang L, Ke Y. The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes. J Nutr Biochem 2009;20:860-865.
122. Qian ZM, Chang YZ, Leung G, Du JR, Zhu L, Wang Q, Niu L, Xu YJ, Yang L, Ho KP, Ke Y. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim Biophys Acta 2007;1772:527-532.
123. Isoda M, Hanawa H, Watanabe R, Yoshida T, Toba K, Yoshida K, Kojima M, Otaki K, Hao K, Ding L, Tanaka K, Takayama T, Kato K, Okura Y, Kodama M, Ota Y, Hayashi J, Aizawa Y. Expression of the peptide hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial infarction. J Nutr Biochem 2010;21:749-756.
124. Rossi MA, Carillo SV. Electron microscopic study on the cardiac hypertrophy induced by iron deficiency anaemia in the rat. Br J Exp Pathol 1983;64:373-387.
125. Olivetti G, Lagrasta C, Quaini F, Ricci R, Moccia G, Capasso JM, Anversa P. Capillary growth in anemia-induced ventricular wall remodeling in the rat heart. Circ Res 1989;65:1182-1192.
126. Olivetti G, Quaini F, Lagrasta C, Ricci R, Tiberti G, Capasso JM, Anversa P. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 1992;141: 227-239.
127. Medeiros DM, Beard JL. Dietary iron deficiency results in cardiac eccentric hypertrophy in rats. Proc Soc Exp Biol Med 1998;218:370-375.
128. Chvapil M, Hurych J, Ehrlichova E. The effect of iron deficiency on the synthesis of collagenous and non-collagenous proteins in wound granulation tissue and in the heart of rats. Exp Med Surg 1968;26:52-60.
129. Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 2011;58:474-480.
130. Boulton FE. The myoglobin content of human skeletal muscle. Br J Haematol 1973;25:281.
131. Polonifi A, Politou M, Kalotychou V, Xiromeritis K, Tsironi M, Berdoukas V, Vaiopoulos G, Aessopos A. Iron metabolism gene expression in human skeletal muscle. Blood Cells Mol Dis 2010;45:233-237.
132. Robach P, Cairo G, Gelfi C, Bernuzzi F, Pilegaard H, Vigano A, Santambrogio P, Cerretelli P, Calbet JA, Moutereau S, Lundby C. Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. Blood 2007;109:4724-4731.
133. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr 1986;6:13-40.
134. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982;306: 1520-1528.
135. Brownlie T IV, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004;79:437-443.
136. Brownlie T IV, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002;75:734-742.
137. Hinton PS, Giordano C, Brownlie T, Haas JD. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000;88:1103-1111.
138. Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 2003; 77:441-448.
139. McLane JA, Fell RD, McKay RH, Winder WW, Brown EB, Holloszy JO. Physiological and biochemical effects of iron deficiency on rat skeletal muscle. Am J Physiol 1981;241:C47-C54.
140. Willis WT, Brooks GA, Henderson SA, Dallman PR. Effects of iron deficiency and training on mitochondrial enzymes in skeletal muscle. J Appl Physiol 1987; 62:2442-2446.
141. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 1982;242:E418-E427.
142. Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447-453.
143. Hinton PS, Sinclair LM. Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007;61:30-39.
144. Com?n-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail 2009;15:727-735.
145. Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN. Anemia in chronic heart failure. Congest Heart Fail 2009;15:87-92.
146. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008;21:236-242.